FDA grants priority review for colon cancer treatment combination.

The U.S. FDA has accepted a supplemental biologics license application for atezolizumab combined with chemotherapy. This combination is intended for adjuvant treatment of stage III colon cancer with specific genetic markers. The decision is based on trial data showing a significant reduction in disease recurrence or death, potentially offering a new treatment option.